Tan Joanne Sh, Yeo Chia-Rou, Popovich David G
Department of Chemistry, National University of Singapore, Singapore, Singapore.
National University Hospital, National University of Singapore, Singapore, Singapore.
Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437. doi: 10.1007/s00253-017-8295-4. Epub 2017 May 6.
Ginsenosides are believed to be the principal components behind the pharmacological actions of ginseng, and their bioactive properties are closely related to the type, position, and number of sugar moieties attached to the aglycone; thus, modification of the sugar chains may markedly change their biological activities. In this study, major protopanaxadiol type ginsenosides (PD) Rb1, Rc, and Rb2 were isolated from Panax ginseng and were transformed using two probiotic strains namely Bifidobacterium lactis Bi-07 and Lactobacillus rhamnosus HN001 to obtain specific deglycosylated ginsenosides. It was demonstrated that B. lactis transformed ginsenosides Rb1, Rc, and Rb2 to Rd within 1 h of fermentation and rare ginsenoside F2 by the conversion of Rd after 12-h fermentation. The maximum Rd concentration was 147.52 ± 1.45 μg/mL after 48-h fermentation as compared to 45.85 ± 0.71 μg/mL before fermentation. In contrast, L. rhamnosus transformed Rb1, Rc, and Rb2 into Rd as the final metabolite after 72-h fermentation. B. lactis displayed significantly (p < 0.05) higher β-glucosidase activity against p-nitrophenyl-β-glucopyranoside than L. rhamnosus and higher bioconversion efficiency during fermentation. The present study suggests that the fermentation of major PD type ginsenosides with B. lactis Bi-07 may serve as an effective means to afford bioactive deglycosylated ginsenosides and to create novel ginsenoside extracts.
人参皂苷被认为是人参药理作用的主要成分,其生物活性特性与苷元上连接的糖部分的类型、位置和数量密切相关;因此,糖链的修饰可能会显著改变其生物活性。在本研究中,从人参中分离出主要的原人参二醇型人参皂苷(PD)Rb1、Rc和Rb2,并使用两种益生菌菌株,即乳酸双歧杆菌Bi-07和鼠李糖乳杆菌HN001进行转化,以获得特定的去糖基化人参皂苷。结果表明,乳酸双歧杆菌在发酵1小时内将人参皂苷Rb1、Rc和Rb2转化为Rd,并在发酵12小时后通过Rd的转化生成稀有皂苷F2。发酵48小时后,最大Rd浓度为147.52±1.45μg/mL,而发酵前为45.85±0.71μg/mL。相比之下,鼠李糖乳杆菌在发酵72小时后将Rb1、Rc和Rb2转化为最终代谢产物Rd。乳酸双歧杆菌对β-硝基苯基-β-吡喃葡萄糖苷的β-葡萄糖苷酶活性显著高于鼠李糖乳杆菌(p<0.05),且在发酵过程中的生物转化效率更高。本研究表明,用乳酸双歧杆菌Bi-07发酵主要的PD型人参皂苷可能是获得具有生物活性的去糖基化人参皂苷和创造新型人参皂苷提取物的有效手段。